母体给予中枢神经系统选择性索贝替罗前药Sob-AM2在MCT8缺陷小鼠胎儿中发挥甲状腺激素样效应
研究在携带Mct8/Dio2双敲除胎鼠的孕鼠中,从胚胎第12.5天起分别给予索贝替罗1 mg/kg/天或Sob-AM2 0.3 mg/kg/天共7天。索贝替罗导致自然流产,而Sob-AM2可穿过胎盘和血脑屏障,在胎肝和胎脑上调T3依赖基因表达。
要点
- 母体索贝替罗治疗导致自然流产。
- Sob-AM2可穿过胎盘及脑屏障,在Mct8/Dio2敲除胎组织中发挥甲状腺激素样效应。
- Sob-AM2在胎脑上调Hr、Shh、Dio3、Kcnj10、Klf9和Faah等T3依赖基因表达。
核心结论
- 母体给予Sob-AM2可穿过胎盘屏障并进入胎儿组织包括脑,在MCT8缺失情况下通过调节T3依赖基因表达发挥甲状腺激素样作用。
- Sob-AM2有潜力从胎儿阶段应对MCT8缺陷特征性的脑甲状腺功能减退,并预防MCT8缺陷胎脑的神经发育异常。
研究设计与样本
- 研究为小鼠模型研究,使用携带Mct8/Dio2双敲除胎鼠的孕鼠作为MCT8缺陷模型。
- 孕鼠从胚胎第12.5天(E12.5)起分别接受索贝替罗1 mg/kg体重/天或Sob-AM2 0.3 mg/kg体重/天共7天。
- 对照为携带野生型胎鼠和携带Mct8/Dio2敲除胎鼠的孕鼠每日皮下注射赋形剂。
- 孕鼠甲状腺激素水平用酶联免疫吸附试验(ELISA)测定,样本在E18.5提取,用实时聚合酶链反应测定胎盘、胎肝和胎脑皮质中T3依赖基因表达。
主要发现
- 母体索贝替罗治疗导致自然流产。
- Sob-AM2治疗可穿过胎盘和脑屏障,在Mct8/Dio2敲除胎组织中发挥甲状腺激素样效应。
- Sob-AM2治疗不影响胎盘中分析的T3靶基因表达,但通过增加Dio1和Dio3基因表达在胎肝中介导甲状腺激素样效应。
- Sob-AM2治疗增加Mct8/Dio2敲除胎脑中Hr、Shh、Dio3、Kcnj10、Klf9和Faah等多个T3依赖基因的表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Monocarboxylate transporter 8 (MCT8) deficiency is a rare X-linked disease where patients exhibit peripheral hyperthyroidism and cerebral hypothyroidism, which results in severe neurological impairments. These brain defects arise from a lack of thyroid hormones (TH) during critical stages of human brain development. Treatment options for MCT8-deficient patients are limited and none have been able to prevent or ameliorate effectively the neurological impairments. This study explored the effects of the TH agonist sobetirome and its CNS-selective amide prodrug, Sob-AM2, in the treatment of pregnant dams carrying fetuses lacking Mct8 and deiodinase type 2 (Mct8/Dio2 KO), as a murine model for MCT8 deficiency. Methods: Pregnant dams carrying Mct8/Dio2 KO fetuses were treated with 1 mg of sobetirome/kg body weight/day, or 0.3 mg of Sob-AM2/kg body weight/day for 7 days, starting at embryonic day 12.5 (E12.5). As controls, pregnant dams carrying wild-type and pregnant dams carrying Mct8/Dio2 KO fetuses were treated with daily subcutaneous injections of vehicle. Dams TH levels were measured by enzyme-linked immunosorbent assay (ELISA). Samples were extracted at E18.5 and the effect of treatments on the expression of triiodothyronine (T3)-dependent genes was measured in the placenta, fetal liver, and fetal cerebral cortex by real-time polymerase chain reaction. Results: Maternal sobetirome treatment led to spontaneous abortions. Sob-AM2 treatment, however, was able to cross the placental as well as the brain barriers and exert thyromimetic effects in Mct8/Dio2 KO fetal tissues. Sob-AM2 treatment did not affect the expression of the T3-target genes analyzed in the placenta, but it mediated thyromimetic effects in the fetal liver by increasing the expression of Dio1 and Dio3 genes. Interestingly, Sob-AM2 treatment increased the expression of several T3-dependent genes in the brain such as Hr, Shh, Dio3, Kcnj10, Klf9, and Faah in Mct8/Dio2 KO fetuses. Conclusions: Maternal administration of Sob-AM2 can cross the placental barrier and access the fetal tissues, including the brain, in the absence of MCT8, to exert thyromimetic actions by modulating the expression of T3-dependent genes. Therefore, Sob-AM2 has the potential to address the cerebral hypothyroidism characteristic of MCT8 deficiency from fetal stages and to prevent neurodevelopmental alterations in the MCT8-deficient fetal brain.
引用
- Valcárcel-Hernández V, Guillén-Yunta M, Scanlan TS, et al. Maternal Administration of the CNS-Selective Sobetirome Prodrug Sob-AM2 Exerts Thyromimetic Effects in Murine MCT8-Deficient Fetuses. Thyroid. 2023. PMID: 36792926. doi:10.1089/thy.2022.0612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。